Physician profile
Devin Kelley
NPI 1548853377
$1,466.79
in general payments reported to CMS, 2019-2025
16 companies · $398 in 2025
The $398 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $410 · 2023: $141 · 2024: $518 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,057.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $536.22 | 2022-2025 | Lifevest |
| Cvrx, INC. | $285.01 | 2024-2025 | Barostim Neo System |
| Astrazeneca Pharmaceuticals Lp | $226.55 | 2022 | |
| Heartflow, INC. | $143.54 | 2024 | |
| Medtronic, INC. | $51.00 | 2023-2024 | Venaseal |
| Pfizer INC. | $29.76 | 2025 | |
| Bridgebio Pharma, INC. | $25.11 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $23.06 | 2024 | Arcalyst |
| Abbvie INC. | $22.85 | 2024 | |
| Amgen INC. | $20.34 | 2025 | Repatha |
| Scpharmaceuticals INC. | $18.87 | 2023 | |
| Bard Peripheral Vascular, INC. | $18.12 | 2025 | Venovo |
| Acella Pharmaceuticals, LLC | $18.08 | 2025 | NP Thyroid 60 |
| Merck Sharp & Dohme LLC | $17.66 | 2024 | Verquvo |
| Cardiovascular Systems INC. | $17.19 | 2023 | Diamondback Coronary |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $13.43 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Kelley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.